Tsumura & Co. (4540.T) Bundle
Who's buying Tsumura & Co. (4540.T) and why? Major moves tell a story: BlackRock Inc. boosted its holding by 150,000 shares in April 2023 while The Vanguard Group trimmed 100,000 shares in March 2023 and Nomura Asset Management added 75,000 shares in May 2023, signaling divergent institutional views against a backdrop of unusually steady risk metrics and robust results - Tsumura's beta is a mere 0.031, revenue for FY ending March 31, 2025 reached 181.09 billion yen (a 20.05% year-on-year rise) with operating profit doubling, market capitalization stood at 281.88 billion yen and the stock traded at 3,792.00 yen on December 12, 2025; governance and ownership remain concentrated (The Master Trust Bank of Japan held 12,215,000 shares, 15.96% as of March 31, 2023; BANK OF CHINA (HONG KONG) LIMITED‑PING AN LIFE held 5,000,000 shares, 6.51%), while corporate fundamentals show 76,758,362 issued shares out of 250,000,000 authorized, 30,142 million yen in capital stock, 4,138 employees and a decrease in total shareholders to 18,103 as of March 31, 2024 - all of which frame why conservative investors drawn to Kampo-focused pharmaceutical stability and growth are paying close attention to Tsumura's next chapters
Tsumura & Co. (4540.T): Who Invests in Tsumura & Co. (4540.T) and Why?
Tsumura & Co. (4540.T) attracts a mix of global institutional investors, conservative income-seeking funds and specialist healthcare investors due to its niche in traditional Kampo medicines, low market volatility and recent strong financial performance.- Global asset managers - e.g., BlackRock Inc. increased its stake by 150,000 shares in April 2023, signaling confidence in Tsumura's growth outlook and defensive characteristics.
- Index and passive funds - The Vanguard Group sold 100,000 shares in March 2023, likely reflecting tactical rebalancing or short-term volatility rather than a long-term change in view.
- Japan-focused asset managers - Nomura Asset Management raised its stake by 75,000 shares in May 2023, indicating conviction after positive earnings and near-term growth prospects.
- Conservative/low-volatility investors - Tsumura's reported beta of 0.031 makes it attractive to portfolios prioritizing downside protection and low correlation with broader equity swings.
- Healthcare and specialty investors - The company's unique positioning in Kampo medicines draws specialized pharma investors looking for differentiated product pipelines and stable demand.
| Investor | Action | Date | Share Change | Interpretation |
|---|---|---|---|---|
| BlackRock Inc. | Increased stake | April 2023 | +150,000 | Confidence in growth prospects / quality defensive holding |
| The Vanguard Group | Sold shares | March 2023 | -100,000 | Possible rebalancing amid short-term volatility |
| Nomura Asset Management | Increased stake | May 2023 | +75,000 | Post-earnings buy reflecting growth conviction |
- Financial performance that attracts investors:
- Net sales growth: +20.1% (FY 2025)
- Operating profit: doubled year-over-year (FY 2025)
- Risk/return profile:
- Beta: 0.031 - suggests minimal market volatility, appealing for capital preservation strategies.
- Revenue stability from established Kampo products supports predictable cash flow and dividend potential.
Tsumura & Co. (4540.T) Institutional Ownership and Major Shareholders of Tsumura & Co. (4540.T)
Institutional holders and a few major corporate investors dominate Tsumura & Co. (4540.T)'s register, reflecting concentrated trust-account holdings and notable strategic positions by insurer-linked entities. Key ownership facts and headline corporate figures as of the fiscal year ends follow.
- The Master Trust Bank of Japan, Ltd. (Trust Account) - 12,215,000 shares (15.96%) as of March 31, 2023.
- BANK OF CHINA (HONG KONG) LIMITED - PING AN LIFE INSURANCE COMPANY OF CHINA, LIMITED - 5,000,000 shares (6.51%) as of March 31, 2023.
- Total shareholders decreased by 2,334 to 18,103 as of March 31, 2024, indicating consolidation or share accumulation by larger holders.
| Metric | Value | As of |
|---|---|---|
| Authorized common stock | 250,000,000 shares | March 31, 2024 |
| Issued common stock | 76,758,362 shares | March 31, 2024 |
| Capital stock | 30,142 million yen | March 31, 2024 |
| Number of employees | 4,138 | March 31, 2024 |
| Major shareholder - The Master Trust Bank of Japan, Ltd. (Trust Account) | 12,215,000 shares (15.96%) | March 31, 2023 |
| Major shareholder - BANK OF CHINA (HONG KONG) LIMITED - PING AN LIFE INSURANCE CO. | 5,000,000 shares (6.51%) | March 31, 2023 |
| Total number of shareholders | 18,103 (decrease of 2,334) | March 31, 2024 vs prior year |
For broader context on corporate history, ownership structure and business model, see: Tsumura & Co.: History, Ownership, Mission, How It Works & Makes Money
Tsumura & Co. (4540.T) - Key Investors and Their Impact on Tsumura & Co. (4540.T)
Tsumura & Co. (4540.T) presents a distinctive investor profile driven by a mix of global asset managers and domestic strategic holders. Institutional moves in 2023-2025 have shaped market perception and likely influenced governance, liquidity and strategic planning.- BlackRock Inc.: increased stake in April 2023 - signaled institutional confidence and potential for greater engagement with corporate governance and long-term strategy.
- The Vanguard Group: sold shares in March 2023 - contributed to short-term selling pressure and heightened intraday/weekly volatility around the announcement.
- Nomura Asset Management: increased stake in May 2023 - reinforced domestic investor conviction in Tsumura's growth prospects and may have supported board-level discussions and strategic continuity.
| Investor | Action | Date | Likely Immediate Impact | Potential Governance/Strategic Impact |
|---|---|---|---|---|
| BlackRock Inc. | Increased stake | April 2023 | Positive signal to market; buy-side support | Increased influence on governance engagement, proxy votes |
| The Vanguard Group | Sold shares | March 2023 | Short-term downward price pressure; higher volatility | Reduced passive-holder support; potential shift in liquidity profile |
| Nomura Asset Management | Increased stake | May 2023 | Domestic vote of confidence; stabilizing investor base | Stronger alignment with management on growth strategy |
- Low market volatility: beta of 0.031 - appeals to conservative, income- and capital-preservation-focused investors.
- Growth with stability: FY2025 results showing a 20.1% rise in net sales and operating profit roughly doubling - draws both value and growth-oriented institutional investors.
- Niche product moat: focus on traditional Japanese Kampo medicines gives Tsumura a differentiated product set within the global pharmaceutical/consumer health market, appealing to investors seeking defensible, specialized revenue streams.
| Metric | Value / Change |
|---|---|
| Beta (1Y) | 0.031 |
| Net sales (FY2025 YoY) | +20.1% |
| Operating profit (FY2025 YoY) | ≈2x (doubling) |
| Primary focus | Kampo medicines (traditional Japanese herbal formulations) |
- Global passive/ETF holders - provide stable, low-turnover base but sales (as seen with Vanguard) can amplify short-term volatility.
- Active global managers (e.g., BlackRock) - can increase scrutiny and push for governance improvements or strategic disclosure enhancements.
- Domestic asset managers (e.g., Nomura) - often back longer-term strategic initiatives and lend credibility to expansion plans in Japan and Asia.
Tsumura & Co. (4540.T) - Market Impact and Investor Sentiment
Tsumura & Co. (4540.T) has seen notable investor interest driven by strong FY2025 results and defensive market characteristics. On December 12, 2025 the stock traded at 3,792.00 yen, with a market capitalization of 281.88 billion yen - figures that reflect renewed confidence in the company's growth trajectory and niche positioning in traditional Japanese Kampo medicines.- Revenue momentum: FY ending March 31, 2025 revenue of 181.09 billion yen, up 20.05% year-over-year.
- Profitability improvement: operating profit doubled in FY2025, signaling margin recovery and operational leverage.
- Risk profile: a very low beta of 0.031 indicates minimal correlation with broader market swings, attracting risk-averse and income-focused investors.
- Strategic moat: focus on Kampo medicines offers differentiated exposure within the global pharmaceutical landscape, appealing to thematic and niche healthcare investors.
| Metric | Value | Context/Implication |
|---|---|---|
| Share Price (12‑Dec‑2025) | 3,792.00 yen | Reflects positive near-term sentiment |
| Market Capitalization | 281.88 billion yen | Mid-cap scale with specialty pharma positioning |
| Revenue (FY ended 31 Mar 2025) | 181.09 billion yen | +20.05% YoY growth |
| Operating Profit (FY2025) | Doubled vs FY2024 | Indicates strong margin expansion |
| Beta | 0.031 | Low volatility profile vs market |
| Primary Business | Traditional Kampo medicines & related pharmaceuticals | Niche, defensible market presence |
- Institutional buyers: drawn by improving fundamentals, doubled operating profit and stable cash flows from established product lines.
- Conservative/retail investors: attracted to low beta (0.031) and defensive characteristics of a healthcare specialty focused on traditional medicines.
- Thematic and specialist funds: interested in Kampo/IPR ownership and unique product pipelines that diversify typical pharma exposure.
- Dividend/income-focused investors: the combination of steady revenues and improved profitability supports favorable payout dynamics.
Tsumura & Co. (4540.T) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.